- The aging of the global population will likely lead to a rising incidence of cancer over the next 15 years and beyond despite well-publicized initiatives to reduce exposure to cancer risks. We expect new cancer cases to outpace population growth by a factor of 3:1. The market for oncology drugs exceeds USD 100bn and should continue to grow well above GDP.
- Recent developments in understanding cancer biology and the immune system have led to the beginning of a new era in cancer treatment. The first wave of immuno-oncology drugs is now established in the market and many new drug candidates are being studied that could be combined with them.
- We expect 2018 to be a big year for oncology. While we stress the long-term nature of drug development, we expect a wave of important clinical data for the theme this year, notably significant late-stage trial results in lung-cancer treatment. On the commercial front, the first sales of personalized cancer treatments (CAR-T) will be closely watched.
According to the World Health Organization (WHO), over 14 million new cases of cancer occurred globally in 2012 and 8.8 million cancer deaths in 2015. Despite great strides made in diagnosis and treatment, cancer remains a leading cause of death.